PH12018502137A1 - Anti-complement factor bb antibodies and uses thereof - Google Patents
Anti-complement factor bb antibodies and uses thereofInfo
- Publication number
- PH12018502137A1 PH12018502137A1 PH12018502137A PH12018502137A PH12018502137A1 PH 12018502137 A1 PH12018502137 A1 PH 12018502137A1 PH 12018502137 A PH12018502137 A PH 12018502137A PH 12018502137 A PH12018502137 A PH 12018502137A PH 12018502137 A1 PH12018502137 A1 PH 12018502137A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibodies
- complement factor
- complement
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317897P | 2016-04-04 | 2016-04-04 | |
| PCT/US2017/025784 WO2017176651A1 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018502137A1 true PH12018502137A1 (en) | 2019-09-23 |
Family
ID=60000646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018502137A PH12018502137A1 (en) | 2016-04-04 | 2018-10-04 | Anti-complement factor bb antibodies and uses thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10934347B2 (https=) |
| EP (1) | EP3452510A4 (https=) |
| JP (3) | JP6967528B2 (https=) |
| KR (2) | KR20240096672A (https=) |
| CN (2) | CN109563158B (https=) |
| AU (2) | AU2017246794B2 (https=) |
| BR (1) | BR112018070357A2 (https=) |
| CA (1) | CA3019332A1 (https=) |
| CL (1) | CL2018002810A1 (https=) |
| CO (1) | CO2018010827A2 (https=) |
| CR (1) | CR20180529A (https=) |
| DO (1) | DOP2018000219A (https=) |
| EA (1) | EA201892225A1 (https=) |
| EC (1) | ECSP18082302A (https=) |
| IL (3) | IL311675A (https=) |
| MA (1) | MA44878A (https=) |
| MX (2) | MX2018012176A (https=) |
| MY (1) | MY194603A (https=) |
| PE (1) | PE20190209A1 (https=) |
| PH (1) | PH12018502137A1 (https=) |
| SG (1) | SG11201808525UA (https=) |
| TN (1) | TN2018000341A1 (https=) |
| WO (1) | WO2017176651A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012016073A2 (en) | 2010-07-28 | 2012-02-02 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| LT3325011T (lt) | 2015-07-24 | 2021-01-25 | Gliknik Inc. | Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu |
| JP6967528B2 (ja) | 2016-04-04 | 2021-11-17 | バイオベラティブ ユーエスエー インコーポレイテッド | 抗補体Ｂｂ因子抗体及びその使用 |
| CA3043251A1 (en) * | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| CN110177802A (zh) | 2016-12-09 | 2019-08-27 | 格利克尼克股份有限公司 | 多聚化stradomer GL-2045的制造优化 |
| US11690919B2 (en) * | 2017-01-17 | 2023-07-04 | The Texas A&M University System | Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells |
| CN111527105B (zh) * | 2017-10-11 | 2024-10-25 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| US11905533B2 (en) | 2017-12-19 | 2024-02-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for delivery of viral vectors across the blood-brain barrier |
| KR20220042128A (ko) * | 2019-06-27 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도 |
| AR122286A1 (es) * | 2019-07-17 | 2022-08-31 | Gemini Therapeutics Sub Inc | Anticuerpos potenciadores del factor h y usos de estos |
| US20230050339A1 (en) * | 2020-02-18 | 2023-02-16 | Children's Hospital Medical Center | Compositions and methods for treating liver disease |
| KR20230004686A (ko) * | 2020-04-20 | 2023-01-06 | 젠자임 코포레이션 | 인간화 항-보체 인자 Bb 항체 및 그의 용도 |
| WO2022066774A1 (en) | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| KR20060099543A (ko) | 1994-12-09 | 2006-09-19 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| AU4188196A (en) | 1994-12-22 | 1996-07-10 | Nissan Chemical Industries Ltd. | Organobismuth derivatives and process for producing the same |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| ES2166097T5 (es) | 1996-08-27 | 2007-03-16 | Novartis Vaccines And Diagnostics, Inc. | Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| AR014621A1 (es) | 1997-12-12 | 2001-03-28 | Macromed Inc | Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| AU2005212369B2 (en) | 2004-02-10 | 2011-06-23 | Musc Foundation For Research Development | Inhibition of factor B, the alternative complement pathway and methods related thereto |
| KR101699142B1 (ko) | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| HRP20130494T1 (en) | 2005-12-20 | 2013-08-31 | Sbi Biotech Co., Ltd. | Anti-ilt7 antibody |
| JP2009520468A (ja) * | 2005-12-23 | 2009-05-28 | ヴィヴェンティア バイオテック インコーポレーティッド | 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用 |
| US8981060B2 (en) * | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| US8158762B2 (en) * | 2007-11-08 | 2012-04-17 | Genentech, Inc. | Anti-factor B antibodies and their uses |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| US8784819B2 (en) | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| BR112014009962A2 (pt) | 2011-10-27 | 2019-09-24 | Nkt Therapeutics Inc | anticorpos humanizados para inkt |
| PE20190658A1 (es) | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| WO2013152020A1 (en) | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
| WO2014044793A2 (en) * | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| BR112015019909A2 (pt) | 2013-02-22 | 2017-08-29 | Abbvie Stemcentrx Llc | Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit |
| US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| AU2015223056B2 (en) * | 2014-02-27 | 2020-10-01 | Allergan, Inc. | Complement Factor Bb antibodies |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| JP6967528B2 (ja) | 2016-04-04 | 2021-11-17 | バイオベラティブ ユーエスエー インコーポレイテッド | 抗補体Ｂｂ因子抗体及びその使用 |
| CN111527105B (zh) | 2017-10-11 | 2024-10-25 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| KR20230004686A (ko) | 2020-04-20 | 2023-01-06 | 젠자임 코포레이션 | 인간화 항-보체 인자 Bb 항체 및 그의 용도 |
-
2017
- 2017-04-03 JP JP2018552076A patent/JP6967528B2/ja active Active
- 2017-04-03 IL IL311675A patent/IL311675A/en unknown
- 2017-04-03 KR KR1020247018546A patent/KR20240096672A/ko active Pending
- 2017-04-03 PE PE2018001946A patent/PE20190209A1/es unknown
- 2017-04-03 EP EP17779607.5A patent/EP3452510A4/en active Pending
- 2017-04-03 MY MYPI2018001682A patent/MY194603A/en unknown
- 2017-04-03 US US16/091,447 patent/US10934347B2/en active Active
- 2017-04-03 TN TNP/2018/000341A patent/TN2018000341A1/en unknown
- 2017-04-03 WO PCT/US2017/025784 patent/WO2017176651A1/en not_active Ceased
- 2017-04-03 AU AU2017246794A patent/AU2017246794B2/en active Active
- 2017-04-03 EA EA201892225A patent/EA201892225A1/ru unknown
- 2017-04-03 MX MX2018012176A patent/MX2018012176A/es unknown
- 2017-04-03 CN CN201780029742.9A patent/CN109563158B/zh active Active
- 2017-04-03 BR BR112018070357-5A patent/BR112018070357A2/pt active Search and Examination
- 2017-04-03 IL IL262010A patent/IL262010B/en unknown
- 2017-04-03 SG SG11201808525UA patent/SG11201808525UA/en unknown
- 2017-04-03 CA CA3019332A patent/CA3019332A1/en active Pending
- 2017-04-03 KR KR1020187031483A patent/KR102673420B1/ko active Active
- 2017-04-03 IL IL295288A patent/IL295288B2/en unknown
- 2017-04-03 MA MA044878A patent/MA44878A/fr unknown
- 2017-04-03 CR CR20180529A patent/CR20180529A/es unknown
- 2017-04-03 CN CN202210862505.3A patent/CN116790614A/zh active Pending
-
2018
- 2018-10-03 CL CL2018002810A patent/CL2018002810A1/es unknown
- 2018-10-04 PH PH12018502137A patent/PH12018502137A1/en unknown
- 2018-10-04 MX MX2023007149A patent/MX2023007149A/es unknown
- 2018-10-04 DO DO2018000219A patent/DOP2018000219A/es unknown
- 2018-10-09 CO CONC2018/0010827A patent/CO2018010827A2/es unknown
- 2018-10-31 EC ECSENADI201882302A patent/ECSP18082302A/es unknown
-
2021
- 2021-01-19 US US17/151,860 patent/US11851482B2/en active Active
- 2021-09-10 JP JP2021147485A patent/JP7326393B2/ja active Active
-
2023
- 2023-08-02 JP JP2023126155A patent/JP2023139289A/ja active Pending
- 2023-11-08 US US18/504,416 patent/US20240228599A1/en active Pending
-
2024
- 2024-09-30 AU AU2024224000A patent/AU2024224000A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| PH12019502283A1 (en) | Anti-lag3 antibodies | |
| PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
| MX2022003273A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| EP4480577A3 (en) | Structured elements and methods of use | |
| TW201713686A (en) | Methods for preparing modified von Willebrand factor |